Table 1.
Study cohort characteristics.
| Study group |
HC (n = 56) |
PID (n = 55) |
HIV (n = 50) |
HSCT (n = 52) |
SOT (n = 51a) |
CLL (n = 65) |
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Subgroup | >60 yrs | 40–59 yrs | 18–39 yrs | CVID | XLA | Monogenic disease | CD4-cytopenia | Other | ≤CD4 300 | >CD4 300 | Early | Intermediate | Late | ≤6 mo w/MMF | >6 mo w/MMF | >6 mo w/o MMF | Ibrutinib | Off Ibrutinib | Indolent | BR/FCR |
| Study subjects [n] | 21 | 19 | 16 | 33 | 2 | 5 | 9 | 6 | 11 | 39 | 3 | 8 | 41 | 17 | 14 | 20 | 15 | 8 | 25 | 17 |
| Demography | ||||||||||||||||||||
| Age in years at inclusion [median, IQR] | 70 (68–75) | 55 (52–57) | 32 (30–34) | 53 (48–62) | 43 (41–45) | 39 (30–41) | 60 (54–73) | 57 (49–64) | 57 (48–67) | 54 (46–68) | 59 (56–64) | 60 (49–63) | 64 (54–69) | 55 (50–61) | 53 (41–69) | 61 (52–70) | 73 (69–76) | 71 (65–75) | 71 (61–77) | 73 (69–75) |
| Gender [n, % females] | 14 (67%) | 10 (52%) | 8 (50%) | 20 (61%) | 0 (0%) | 4 (80%) | 6 (67%) | 6 (100%) | 4 (36%) | 18 (46%) | 1 (33%) | 4 (50%) | 19 (46%) | 5 (29%) | 8 (57%) | 12 (60%) | 4 (27%) | 3 (38%) | 14 (56%) | 3 (18%) |
| Vaccine doses | ||||||||||||||||||||
| 3 doses [n, %] | 18 (90%) | 17 (90%) | 14 (88%) | 30 (91%) | 2 (100%) | 3 (60%) | 9 (100%) | 4 (66%) | 9 (82%) | 30 (79%) | 3 (100%) | 8 (100%) | 40 (98%) | 17 (100%) | 14 (100%) | 20 (100%) | 15 (100%) | 8 (100%) | 25 (100%) | 14 (82%) |
| 4 doses [n, %] | – | – | – | 24 (73%) | 1 (50%) | 1 (20%) | 6 (67%) | – | – | – | 2 (67%) | 8 (100%) | 25 (61%) | 14 (82%) | 13 (93%) | 15 (75%) | 13 (87%) | 7 (88%) | 17 (68%) | 12 (71%) |
| Days from dose 3 to sampling | ||||||||||||||||||||
| 9 m sampling timepoint [mean, IQR] | 63 (62–74) | 34 (25–46) | 27 (19–37) | 50 (56–82) | 71 (62–80) | 48 (40–60) | 85 (80–96) | 59 (39–86) | 35 (3–60) | 36 (15–53) | 121 (119–122) | 127 (120–139) | 127 (124–136) | 125 (119–138) | 120 (117–136) | 126 (117–145) | 70 (63–82) | 50 (57–66) | 54 (55–75) | 66 (64–78) |
| 12 m sampling timepoint [mean, IQR] | 136 (136–146) | 99 (92–108) | 97 (91–100) | 121 (126–146) | 139 (131–146) | 102 (95–116) | 139 (137–142) | 120 (100–148) | 108 (73–142) | 102 (84–112) | 177 (173–179) | 167 (163–176) | 167 (168–177) | 186 (181–195) | 183 (182–193) | 179 (180–196) | 141 (140–154) | 120 (101–143) | 128 (121–152) | 140 (139–150) |
| Days from dose 4 to sampling | ||||||||||||||||||||
| 12 m sampling timepoint [mean, IQR] | – | – | – | 26 (16–40) | 38 | 14 (14–14) | 29 (20–36) | – | – | – | 38 (35–41) | 26 (25–31) | 35 (28–42) | 41 (30–47) | 37 (28–43) | 36 (28–41) | 28 (29–37) | 25 (12–37) | 27 (22–34) | 27 (22–33) |
| Days between vaccine doses | ||||||||||||||||||||
| Vaccine dose nr 3 and 4 | – | – | – | 115 (98–123) | 116 | 104 | 112 (105–119) | – | – | – | 139 (129–141) | 142 (105–148) | 136 (132–147) | 150 (142–159) | 146 (137–160) | 144 (150–160) | 116 (109–119) | 105 (93–115) | 116 (108–125) | 114 (109–124) |
| Seroconversion (>0.8 AU/ml) | ||||||||||||||||||||
| At 3 m sampling timepoint [%] | 100% | 100% | 100% | 64% | 100% | 50% | 100% | 100% | 75% | 100% | 100% | 75% | 96% | 60% | 40% | 92% | 33% | 57% | 77% | 89% |
| At 12 m sampling timepoint [%] | 100% | 100% | 100% | 90% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 91% | 87% | 100% | 73% | 83% | 91% | 100% |
| SARS-CoV-2 Infections | ||||||||||||||||||||
| PCR/RAT verified COVID-19 [n, % of total] | 2 (11%) | 6 (32%) | 8 (50%) | 15 (46%) | 1 (50%) | 0 (0%) | 1 (11%) | 2 (33%) | 0 (0%) | 6 (16%) | 2 (67%) | 1 (13%) | 5 (12%) | 6 (35%) | 3 (21%) | 2 (10%) | 3 (20%) | 1 (13%) | 7 (28%) | 4 (24%) |
| Nucleocapsid+ (no PCR/RAT verification) COVID-19 [n, % of total] | 4 (21%) | 2 (11%) | 2 (13%) | 5 (15%) | 1 (50%) | 2 (40%) | 2 (22%) | 1 (17%) | 4 (36%) | 6 (16%) | 1 (33%) | 1 (13%) | 4 (10%) | 1 (6%) | 0 (0%) | 1 (5%) | 0 (0%) | 2 (25%) | 0 (0%) | 0 (0%) |
| Total COVID-19 [n, % of total] | 6 (32%) | 8 (42%) | 10 (63%) | 20 (61%) | 2 (100%) | 2 (40%) | 3 (33%) | 3 (50%) | 4 (36%) | 12 (32%) | 3 (100%) | 2 (25%) | 9 (22%) | 7 (41%) | 3 (21%) | 3 (15%) | 3 (20%) | 3 (38%) | 7 (28%) | 4 (24%) |
| Patients requiring hospital care due to COVID-19 [n] | – | – | – | – | 1 | – | – | – | – | – | – | – | 1 | 1 | 1 | – | – | – | 2 | – |
| Immunoglobulin treatment | ||||||||||||||||||||
| Monocloncal antibodies [n] | – | – | – | · | 1 | – | – | – | – | – | – | – | – | 1 | – | – | – | – | 3 | 1 |
| IGRT [n] | – | – | – | 21 | 2 | – | 2 | – | – | – | – | – | 6 | – | – | – | 1 | 1 | – | 2 |
Abbreviations: n: number, IQR: interquartile range, PID: primary immunodeficiency disorders, HIV: human immunodeficiency virus, HSCT: hematopoietic stem cell transplantation, SOT: solid organ transplantation, CLL: chronic lymphocytic leukemia, CVID, common variable immunodeficiency, XLA: X-linked agammaglobulinemia, MMF: mycophenolate mofetil, BR/FCR: Bendamustine and Rituximab/Fludarabine, Cyclophsphamide and Rituximab, IGRT: immunoglobulin replacement therapy, RAT: rapid antigen test.
a
The different transplants in the SOT group (n = 51) were: 32 liver, 16 kidney, 5 kidney + pancreas.